• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

Algeness  VL Clinical Trial Begins

Advanced Aesthetic Technologies, Inc, announces start of Algeness VL clinical trial in China seeking future market approval.

Advanced Aesthetic Technologies, Inc (AAT), a leader in aesthetic gel implant technology, recently announced the start of the clinical trial for Algeness VL (2.5% Agarose Gel) filler in China in partnership with Lanzhou Biotechnique Development Co., LTD (LanDev) and their parent company China National Biotec Group Co., LTD (CNBG). The companies are seeing market approval in China.1 

Algeness is a biomaterial resulting from a manufacturing process consisting of a purified agarose gel (polysaccharide), derived from the purification of agar-agar from red algae, according to the company website. Unlike hyaluronic acid filler, Algeness contains no cross-linked synthetic chemicals (BBDE or PEG) and is 100% natural.2

The study’s purpose is to examine the safety and efficacy of Algeness as treatment for moderate to severe nasolabial folds vs hyaluronic acid fillers, according to a press release announcing the start of the clinical trial.

“China's aesthetics market is growing faster than the global market. The size of the Chinese population and relatively low market penetration of aesthetics and filler treatments in China present enormous potential for future growth,” says Doug Abel, the CEO of AAT in Brookline, Massachusetts. “Our novel Algeness range of dermal fillers is the first 100% natural, biocompatible and fully biodegradable filler on the market to date, which differentiates it from other injectable products.” 

References:

1. Inc AAT. Advanced aesthetic technologies, inc. Announces the treatment of the first patient in a pivotal clinical trial in china with their Algeness® vl (2. 5% agarose gel) filler for the correction of moderate to severe nasolabial folds. Published June 24, 2021. Accessed June 25, 2021. https://www.prnewswire.com/news-releases/advanced-aesthetic-technologies-inc-announces-the-treatment-of-the-first-patient-in-a-pivotal-clinical-trial-in-china-with-their-algeness-vl-2-5-agarose-gel-filler-for-the-correction-of-moderate-to-severe-nasolabial-folds-301319071.html

2. What is algeness. Algeness. Accessed June 29, 2021. https://www.algeness.com/what-is-algeness-natural-and-biodegradable-filler.html 

Related Videos
© 2024 MJH Life Sciences

All rights reserved.